2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 705

Is a Positive Family History of Spondyloarthritis of Value in Patients with Chronic Back Pain? Results from Two Large Early Back Pain Cohorts
Abstract Number: 3193

Is an Intensive Diet and Exercise Regimen Cost-Effective for Obese and Overweight Patients with Symptomatic Knee OA?
Abstract Number: 2734

Is Disease Activity Associated with Negative Illness Perceptions in Early Axial Spondyloarthritis Patients in the Spondyloarthritis Caught Early (SPACE)-Cohort?
Abstract Number: 2004

Is Disease Activity Associated with Work Productivity Loss, Presenteeism and Absenteeism in Patients with Early Axial Spondyloarthritis? Results from the Spondyloarthritis Caught Early (SPACE)-Cohort
Abstract Number: 3051

Is Frailty a Relevant Concept in Systemic Lupus Erythematosus (SLE)?
Abstract Number: 2821

Is Hyperuricemia an Independent Risk Factor for Arterial Thrombosis in Systemic Lupus Erythematosus?
Abstract Number: 2491

Is It Possible to Predict Which Patients Treated with Biologic Agents for Rheumatic Diseases Will Develop Anti-Drug Antibodies ?
Abstract Number: 2198

Is Joint Hypermobility Related to Foot Osteoarthritis and Symptoms?
Abstract Number: 92

Is Patient Support Program (PSP) Participation Associated with Longer Persistence and Greater Adherence Among New Users of Adalimumab?
Abstract Number: 344

Is Rheumatoid Arthritis a Risk Factor for Fractures: A Systematic Review of Observational Studies
Abstract Number: 1178

Is Subclinical Atherosclerosis Prevalent in a French Patient Cohort with Systemic Lupus Erythematosus?
Abstract Number: 1410

Is the Self-Assessment of Disease Activity (auto-DAS28) By Patients a Feasible and Acceptable Measure over the Long Term in Rheumatoid Arthritis (RA)? Three-Year Follow-up of a Nurse-Led Program in 771 Patients with Established RA
Abstract Number: 2777

Is There a Difference in Clinical Features and Burden of Disease in Patients with Axial Spondyloarthritis with and without Extra-Articular Manifestations?
Abstract Number: 2389

Is There a Difference in the Presentation of Diffuse and Limited Subtype in Childhood? Results from the Juvenile Scleroderma Inception Cohort
Abstract Number: 858

Is There a Place for Repetitive 18f-Fluorodeoxyglucose Positron Emission Tomography in Giant-Cell Arteritis with Large-Vessel Involvement?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].